TUKYSA Added to First-Line Maintenance Therapy Extends Median Progression-Free Survival by Over 8 Months in Patients with HER2+ Metastatic Breast Cancer

Core Insights - Pfizer Inc. announced detailed results from the Phase 3 HER2CLIMB-05 trial for TUKYSA® (tucatinib) as a first-line maintenance treatment in HER2+ metastatic breast cancer patients [1] Summary by Categories Clinical Trial Results - The primary endpoint analysis demonstrated a 35.9% reduction in the risk of disease progression or death among patients receiving TUKYSA® [1]